View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Sanofi: 1 director

A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

Lvmh Moet Hennessy Louis Vuitton SE: 1 director

A director at Lvmh Moet Hennessy Louis Vuitton SE bought 16,134 shares at 785.866EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

 PRESS RELEASE

Press Release: Annual General Meeting of April 30, 2024

Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...

 PRESS RELEASE

Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024

Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2023Distribution d’un dividende en numéraire de 3,76 euros par action, dont la mise en paiement interviendra le 15 mai 2024Composition du Conseil d’administration : renouvellement de deux administrateurs et nomination de trois nouveaux administrateurs indépendants Paris, le 30 avril 2024. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2024, sous la présidence de Frédéric ...

Michael B. Schäfer
  • Michael B. Schäfer

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/30/2024

BHP's bid for Anglo American has confirmed interest from miners in copper in the context of increasingly challenged production and difficulties in fully completing projects. Anglo’s (Neutral) prospects in copper are now better valued and this is also the case for BHP (Neutral vs Underperform) although not so for Rio Tinto (Outperform vs Neutral). Downstream, Nexans and Montana Aerospace are our Top Picks (Outperform) vs Aurubis, Rexel and Prysmian (Neutral). - ...

Michael B. Schäfer
  • Michael B. Schäfer

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 30/04/2024

L’offre de BHP sur Anglo American a confirmé l’intérêt des minières pour le cuivre dans un contexte de tensions croissantes sur la production et de difficultés à faire aboutir les projets. Les perspectives d’Anglo (Neutre) dans le cuivre sont désormais mieux valorisées, c’est aussi le cas de BHP (Neutre vs Sous-performance) mais pas encore assez, selon nous, sur Rio Tinto (Surperformance vs Neutre). En aval, Nexans et Montana Aerospace sont nos valeurs préférées (Surperformance) vs Au...

Juan Ros-Padilla
  • Juan Ros-Padilla

Jeronimo Martins : Q1 EBITDA beats our numbers and the consensus

>Calendar and FX certainly help but let’s not overlook the volume-driven underlying growth - Sales grew at a pace of +19% y-o-y to € 8.1bn (vs +17% in Q4) with the group’s l-f-l expanding at +6% (vs +10% in Q4). By business, Biedronka sales grew +19% to € 5.8bn, accelerating vs Q4 (+19%) helped by the calendar effect (3pp) and the FX (8pp). L-f-L only deteriorated 50bp q-o-q to 4.6% which is remarkable in a disinflationary context and proves right Biedronka’s volume-d...

Jean Danjou
  • Jean Danjou

ODDO : Monday review – Luxury sector

>Topic of the week: the good, the not good and the worrying - From the batch of Q1 results, one outstanding performance stands out, the one of Miu Miu that again grew in excess of 80% this quarter. Astutely combining quiet luxury with fantasy, the sister brand of Prada together with Loewe - part of LVMH F&L - are probably the franchises encapsulating the most the current zeitgeist among young luxury shoppers. It stands for only 22% of the group sales and the reaction ...

Jean Danjou
  • Jean Danjou

ODDO : Monday review – Luxury sector

>Topic of the week: the good, the not good and the worrying - From the batch of Q1 results, one outstanding performance stands out, the one of Miu Miu that again grew in excess of 80% this quarter. Astutely combining quiet luxury with fantasy, the sister brand of Prada together with Loewe - part of LVMH F&L - are probably the franchises encapsulating the most the current zeitgeist among young luxury shoppers. It stands for only 22% of the group sales and the reaction ...

Clement Genelot
  • Clement Genelot

Jeronimo Martins: Q1 topping expectations; price war ongoing in Poland

With Q1 topping expectations in terms of both sales and EBITDA, notably thanks to Biedronla, we foresee a positive share price reaction this morning. But reiterated gloomy FY guidance combined with no early signs of the price war easing in Poland still suggests caution is advisable.

Research Team
  • Research Team

WOOD Daily: JMT PL; CAR PW; MBR PW; SHO PW; TL Macro; UZ Macro; PL Ban...

HEADLINES: • Jeronimo Martins: small beat in 1Q24 NEUTRAL • Inter Cars: 4Q23 net profit in line with prelims, a miss vs. our initial forecasts due to lower gross margin NEUTRAL • Mo-BRUK: 4Q23 earnings call takeaways – supportive 2024E outlook POSITIVE • Shoper: earnings call takeaways – strong April, optimistic on 2024E outlook POSITIVE • Türkiye macro: MPC takes a pause, but hiking cycle not over yet • Uzbekistan macro: CBU keeps rates on hold • Polish banks: Polish Supreme Court reconfirms th...

Charlotte Vaisse ... (+5)
  • Charlotte Vaisse
  • Emmanuel Matot
  • Jean-Baptiste Rouphael
  • Konrad Zomer
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/25/2024

Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...

Charlotte Vaisse ... (+5)
  • Charlotte Vaisse
  • Emmanuel Matot
  • Jean-Baptiste Rouphael
  • Konrad Zomer
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/04/2024

Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Sanofi : Q1 2024 passes without a hitch

>A little better than expected - Sanofi has reported this morning Q1 2024 results a little above forecasts at the level of sales and EPS. As expected, Sanofi suffered from a deeply negative forex effect (-4.3% on the topline and -10.2% on the bottom line).In short, total group sales came to € 10.464 bn vs € 10.272 bn (+2.4%; +6.7% at cc), core EBIT to € 2.843 bn vs € 2.748 bn est. (-14.7%; -4.2% at cc) and core EPS to € 1.78 vs € 1.71 est., down 7.4% at cc (sour...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Sanofi : Le T1 2024 passe sans encombre

>Un peu supérieur aux attentes - Sanofi publie ce matin ses résultats du T1 24 qui s’avèrent un peu au-dessus des attentes au niveau des ventes et de son BPA. Comme attendu Sanofi bénéficie d’un effet changes très négatif (-4.3% en topline et -10.2% en bottom line). Brièvement, les ventes totales du groupe ressortent à 10 464 M€ vs 10 272 M€e (+2.4% ; +6.7% à tcc), son core EBIT à 2 843 M€ vs 2 748 M€e (-14.7% ; -4.2% tcc) pour un Core BPA de 1.78 € vs 1.71 €e e...

Rafael Bonardell
  • Rafael Bonardell

SANOFI: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 1T'24 vs 1T'23: Ventas: 10.464 M euros (+1,4% vs -0,6% consenso); EBIT: 2.843 M euros (-14,7% vs -16,2% consenso).

 PRESS RELEASE

Communiqué de presse : Sanofi réitère ses objectifs financiers pour 20...

Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements                                                                                                                                                                                          Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements Paris, le 25 avril 2024 T1 2024 : Augmentation des ventes de 6,7% à TCC et du BNPA des activités(1) de €1,78 Les ventes de Dupixent ont augmenté de 24,9% à €2 835 mi...

 PRESS RELEASE

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, u...

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness perf...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch